These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12715127)

  • 1. [How effective are PDE-5 inhibitors?].
    Jünemann KP
    Urologe A; 2003 Apr; 42(4):553-8. PubMed ID: 12715127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
    J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
    Mason RG
    J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
    Perimenis P
    Expert Opin Pharmacother; 2005 Jan; 6(1):1-2. PubMed ID: 15709877
    [No Abstract]   [Full Text] [Related]  

  • 7. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
    McCullough A
    Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
    Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
    Seftel AD
    Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil and vardenafil.
    Neumeyer K; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P; Sander GE; Giles TD
    Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.